Alterity Therapeutics Reports Positive Topline Phase 2 Clinical Trial Data
Alterity Therapeutics announced positive topline data from its open-label Phase 2 clinical trial (ATH434-202) of ATH434 in individuals with...
ImmunityBio’s Visionary Approach to Cancer Immunotherapy
In this interview with Bobby Reddy, Chief Medical Officer at ImmunityBio, we explore the company’s groundbreaking work in cancer...
Reshape Lifesciences® Hosts Inaugural Lap-Band® Surgeon Summit
ReShape Lifesciences is hosting its first Lap-Band Surgeon Summit from August 1st to 3rd, 2025, in Nashville, Tennessee. The...
Rinvoq, Gazyva, and Sotyktu Emerge as Front-Runners for Lupus Care
Biologic use for systemic lupus erythematosus (SLE) is increasing, with nearly 40% of moderate-to-severe SLE patients in the U.S....
Qu Biologics’ Immunomodulator Study in Elderly
Qu Biologics has completed enrollment for its RESILIENCE Study, a Phase 2 clinical trial testing QBKPN SSI, a novel...
FDA and EMA Push for Predicting Protocol Deviations. How Psychology Can Help
The site team was blindsided. The patient met every inclusion and exclusion criterion, showed no red flags, and even...
Clearmind Medicine starts the leading Israeli Clinical site
Clearmind Medicine Inc. announced the successful initiation of a clinical trial site at Tel Aviv Sourasky Medical Center (TASMC)...
Windward Bio Launches Global Phase 2 Asthma Trial of WIN378
Windward Bio has launched its Phase 2 POLARIS clinical trial to assess the long-acting dosing of WIN378, an anti-TSLP...
Aquablation® Prostate Cancer Trial: Water IV Procedures Completed
PROCEPT BioRobotics announced the successful completion of three prostate cancer procedures using Aquablation therapy in an ambulatory surgery center...
Recognify’s Phase 2b Trial of Inidascamine Falls Short on Primary Endpoint in CIAS
In a 242-patient Phase 2b trial for cognitive impairment associated with schizophrenia (CIAS), inidascamine (formerly RL-007) failed to meet...